Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Decernotinib |
Synonyms | |
Therapy Description |
Decernotinib (VX-509) is a selective JAK3 inhibitor, which may modulate the immune response (PMID: 25762693). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Decernotinib | VX-509|VX 509|VX509|VRT-831509|Adelatinib | JAK3 Inhibitor 6 | Decernotinib (VX-509) is a selective JAK3 inhibitor, which may modulate the immune response (PMID: 25762693). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 M511I | hematologic cancer | sensitive | Decernotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 M511I were sensitive to treatment with Decernotinib (VX-509) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
JAK3 L875H | hematologic cancer | predicted - sensitive | Decernotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L875H demonstrated some sensitivity to treatment with Decernotinib (VX-509) in culture, but were not as sensitive as cells expressing other JAK3 activating mutations (PMID: 31976485). | 31976485 |
JAK3 L857Q | hematologic cancer | sensitive | Decernotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L857Q were sensitive to treatment with Decernotinib (VX-509) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|